The passage of state laws legalizing the physician-recommended possession and consumption of cannabis by qualified patients has not led to an increase in adolescents’ use of the plant, according to a working paper published by the National Bureau of Economic Research – a non-partisan research organization based in Cambridge, Massachusetts.
Investigators from the University of Colorado at Denver, the University of Oregon, and Montana State University assessed federal data on youth marijuana use and treatment episodes for the years 1993 to 2011 – a time period when 16 states authorized medical cannabis use.
Authors reported, “Our results are not consistent with the hypothesis that the legalization of medical marijuana caused an increase in the use of marijuana among high school students. In fact, estimates from our preferred specification are small, consistently negative, and are never statistically distinguishable from zero.”
A separate analysis published in April in the Journal of Adolescent Health similarly determined, “This study did not find increases in adolescent marijuana use related to legalization of medical marijuana. … This suggests that concerns about ‘sending the wrong message’ may have been overblown.”
Full text of the study, “Medical marijuana laws and teen marijuana use,” is available online here.
Senate members are expected to vote imminently in regard to language that seeks to bar the US Justice Department from interfering in activities that are compliant with state medical cannabis laws.
Senators Rand Paul (R-KY) and Cory Booker (D-NJ) will introduce the bipartisan amendment, which will be similar to language approved by the US House of Representatives earlier this month. As with other legislation, the amendment must be approved by majorities in both legislative chambers before it is sent to the President for approval.
This will be the first time in recent memory that US Senators have ever decided on provisions specific to liberalizing America’s marijuana policies.
It is time that we allowed our unique federalist system to work the way it was intended. Patients and providers should be permitted to engage in state-sanctioned, medical cannabis-related activities free from the threat of federal interference or federal prosecution.
Please write or call your members of Senate today and tell them to stop using taxpayer dollars to target and prosecute state-authorized medical marijuana patients and providers. For your convenience, a pre-written letter will be e-mailed to your Senators when you visit here.
State lawmakers have approved legislation, Senate Bill 155, to fund observational and clinical research assessing the safety and therapeutic efficacy of cannabis. Democrat Gov. John Hickenlooper signed the bill into law today.
The measure establishes a subaccount of up to $10 million within the state’s medical marijuana program fund to be utilized specifically for the purpose of conducting state-sponsored cannabis research. The intent of this new research program is to “gather objective scientific research regarding the efficacy of administering marijuana and its component parts as part of medical treatment.” The law also establishes a ‘scientific advisory council,’ which may include expert participants from around the nation, to evaluate research proposals and make recommendations in regards to funding requests.
“SB 155 invests the dollars collected from medical marijuana fees into a meaningful effort to study the therapeutic and medical benefits of the drug,” stated Democrat Rep. Crisanta Duran, a co-sponsor of the bill, told The Huffington Post. “Patients will benefit from this investment and Colorado will become a national leader in developing medical marijuana research.”
In recent years, only one state — California — has previously earmarked state funding to explicitly sponsor clinical cannabis research. That program, established at various universities statewide, funded numerous clinical trials over the past decade evaluating the efficacy of whole-plant cannabis for a variety of conditions, including multiple sclerosis and neuropathic pain. A review of these trials published in The Open Neurology Journal concluded, “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.”
Earlier this month, the US Drug Enforcement Administration (DEA) publicly announced in the Federal Register that it is increasing its marijuana production quota from 21 kilograms to 650 kilograms (about 1,443 pounds) in order to meet increasing demand for the plant from clinical investigators.
Federal regulations permit a farm at the University of Mississippi to cultivate set quantities of cannabis for use in federally approved clinical trials. Regulators at the DEA, the US Food and Drug Administration, PHS (Public Health Service), and the US National Institute on Drug Abuse must approve any clinical protocol seeking to study the plant’s effects in human subjects — including those trials that are either state or privately funded.
The enactment of medicinal cannabis laws is not associated with any rise in statewide criminal activity and may even be related to reductions in incidences of violent crime, according to data published online in the journal PLoS ONE.
Researchers at the University of Texas at Dallas tracked crime rates across all 50 states between the years between 1990 and 2006, a time period during which 11 states legalized marijuana for medical use. Authors reviewed FBI data to determine whether there existed any association between the passage of medicinal cannabis laws and varying rates of statewide criminal activity, specifically reported crimes of homicide, rape, robbery, assault, burglary, larceny, and auto theft.
Investigators reported that the passage of medical marijuana laws was not associated with an increase in any of the seven crime types assessed, but that liberalized laws were associated with decreases in certain types of violent crime.
“The central finding gleaned from the present study was that MML (medical marijuana legalization) is not predictive of higher crime rates and may be related to reductions in rates of homicide and assault,” authors reported. “Interestingly, robbery and burglary rates were unaffected by medicinal marijuana legislation, which runs counter to the claim that dispensaries and grow houses lead to an increase in victimization due to the opportunity structures linked to the amount of drugs and cash that are present. Although, this is in line with prior research suggesting that medical marijuana dispensaries may actually reduce crime in the immediate vicinity.”
Researchers concluded: “Medical marijuana laws were not found to have a crime exacerbating effect on any of the seven crime types. On the contrary, our findings indicated that MML precedes a reduction in homicide and assault. … In sum, these findings run counter to arguments suggesting the legalization of marijuana for medical purposes poses a danger to public health in terms of exposure to violent crime and property crimes.”
Full text of the study, “The Effect of Medical Marijuana Laws on Crime: Evidence from State Panel Data, 1990-2006,” appears online here.
Nearly 30 states, and the District of Columbia are considering marijuana law reform legislation this year, including bills that cover legalization for adults, decriminalization, medical marijuana and hemp. Some states have a variety of reform bills simultaneously pending such as Arizona which is considering legalization and decriminalization, and Pennsylvania which is considering legalization as well as medical marijuana legislation. Here’s a quick breakdown:
14 states are considering legalization: Arizona, Hawaii, Maryland, Massachusetts, Missouri, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, Vermont, and Wisconsin.
12 states and the District of Columbia are considering decriminalization: Alabama, Arizona, DC, Hawaii, Illinois, Louisiana, Michigan, Missouri, New Hampshire, New York, North Carolina, South Carolina, and Wyoming.
11 states are considering legislation to establish effective medical marijuana programs: Florida, Kansas, Kentucky, Hawaii, Michigan, New York, Pennsylvania, Tennessee, West Virginia, Minnesota and Wisconsin.
3 states are considering allowing industrial hemp cultivation: Indiana, New York, and Tennessee.
Click here to access NORML’s Action Alerts and quickly and easily contact your elected officials to encourage their support of any pending reform bills. Be sure to keep checking NORML’s Take Action Center to see if your state has joined the list!